Literature DB >> 18611860

CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.

Hernan Roca1, Zachary Varsos, Kenneth J Pienta.   

Abstract

Resistance to cell death is a hallmark of cancer. Autophagy is a survival mechanism activated in response to nutrient deprivation; however, excessive autophagy will ultimately induce cell death in a nonapoptotic manner. The present study demonstrates that CCL2 protects prostate cancer PC3 cells from autophagic death, allowing prolonged survival in serum-free conditions. Upon serum starvation, CCL2 induced survivin up-regulation in PC3, DU 145, and C4-2B prostate cancer cells. Both cell survival and survivin expression were stunted in CCL2-stimulated PC3 cells when treated either with the phosphatidylinositol 3-kinase inhibitor LY294002 (2 microm) or the Akt-specific inhibitor-X (Akti-X; 2.5 microm). Furthermore, CCL2 significantly reduced light chain 3-II (LC3-II) in serum-starved PC3; in contrast, treatment with LY294002 or Akti-X reversed the effect of CCL2 on LC3-II levels, suggesting that CCL2 signaling limits autophagy in these cells. Upon serum deprivation, the analysis of LC3 localization by immunofluorescence revealed a remarkable reduction in LC3 punctate after CCL2 stimulation. CCL2 treatment also resulted in a higher sustained mTORC1 activity as measured by an increase in phospho-p70S6 kinase (Thr389). Rapamycin, an inducer of autophagy, both down-regulated survivin and decreased PC3 cell viability in serum-deprived conditions. Treatment with CCL2, however, allowed cells to partially resist rapamycin-induced death, which correlated with survivin protein levels. In two stable transfectants expressing survivin-specific short hairpin RNA, generated from PC3, survivin protein levels controlled both cell viability and LC3 localization in response to CCL2 treatment. Altogether, these findings indicate that CCL2 protects prostate cancer PC3 cells from autophagic death via the phosphatidylinositol 3-kinase/Akt/survivin pathway and reveal survivin as a critical molecule in this survival mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18611860      PMCID: PMC2529129          DOI: 10.1074/jbc.M801073200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

Review 1.  Development by self-digestion: molecular mechanisms and biological functions of autophagy.

Authors:  Beth Levine; Daniel J Klionsky
Journal:  Dev Cell       Date:  2004-04       Impact factor: 12.270

2.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.

Authors:  G Ambrosini; C Adida; D C Altieri
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

3.  Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast.

Authors:  T Noda; Y Ohsumi
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

4.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1.

Authors:  P E Burnett; R K Barrow; N A Cohen; S H Snyder; D M Sabatini
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes.

Authors:  E F Blommaart; J J Luiken; P J Blommaart; G M van Woerkom; A J Meijer
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

Review 6.  Chemokines in the pathogenesis of vascular disease.

Authors:  Israel F Charo; Mark B Taubman
Journal:  Circ Res       Date:  2004-10-29       Impact factor: 17.367

7.  Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.

Authors:  T T Wu; R A Sikes; Q Cui; G N Thalmann; C Kao; C F Murphy; H Yang; H E Zhau; G Balian; L W Chung
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

Review 8.  CCL2 (monocyte chemoattractant protein-1) and cancer.

Authors:  Ilaria Conti; Barrett J Rollins
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

9.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.

Authors:  R D Leek; C E Lewis; R Whitehouse; M Greenall; J Clarke; A L Harris
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

10.  Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway.

Authors:  Mara Fornaro; Janet Plescia; Sophie Chheang; Giovanni Tallini; Yong-M Zhu; Michael King; Dario C Altieri; Lucia R Languino
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

View more
  79 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis.

Authors:  Susanna Choi; Sungyong You; Donghyun Kim; Soo Youn Choi; H Moo Kwon; Hyun-Sook Kim; Daehee Hwang; Yune-Jung Park; Chul-Soo Cho; Wan-Uk Kim
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

3.  Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer.

Authors:  Raju K Mandal; Toshi Agrawal; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-09-30

Review 4.  Survivin at a glance.

Authors:  Sally P Wheatley; Dario C Altieri
Journal:  J Cell Sci       Date:  2019-04-04       Impact factor: 5.285

Review 5.  Association of survivin splice variants with prognosis and treatment of breast cancer.

Authors:  Anastasia Pavlidou; Christos Kroupis; Kleanthi Dimas
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 6.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

7.  Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.

Authors:  S R Sangeetha; Nagendra Singh; John R Vender; Krishnan M Dhandapani
Journal:  Endocrine       Date:  2009-03-17       Impact factor: 3.633

8.  CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

Authors:  Hernan Roca; Zachary S Varsos; Kenneth J Pienta
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.

Authors:  Hernan Roca; Zachary S Varsos; Sudha Sud; Matthew J Craig; Chi Ying; Kenneth J Pienta
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

10.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.